Real-world data of voxelotor for SCD

Voxelotor is a first-in-class therapy for sickle cell disease (SCD) that can directly inhibit sickle hemoglobin (HbS) polymerization and, therefore, decrease sickling. Alan Anderson, MD, Prisma Health, Columbia, SC, discusses the real-world experience evaluating the response to voxelotor in patients with SCD. Clinical data from adult and adolescent patients with SCD treated with voxelotor was collected. Results from this single-center study show that the effects on hemoglobin, total bilirubin, and reticulocyte percentage were similar to those reported in the HOPE trial (NCT03036813), suggesting that patients with SCD benefit from voxelotor therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.